Cubist Systematic Strategies’s TScan Therapeutics TCRX Stock Holding History

Cubist Systematic Strategies’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$76.6K	Sell	42,078 -130,434	-76%	-$231K	﹤0.01%	2808
2025 Q2	$250K	Buy	172,512 +151,672	+728%	+$219K	﹤0.01%	2521
2025 Q1	$28.8K	Sell	20,840 -42,255	-67%	-$91.4K	﹤0.01%	2726
2024 Q4	$192K	Buy	63,095 +30,958	+96%	+$140K	﹤0.01%	2582
2024 Q3	$160K	Buy	+32,137	New	+$194K	﹤0.01%	2621
2024 Q2	–	Sell	-44,308	Closed	-$352K	–	3984
2024 Q1	$352K	Buy	44,308 +18,063	+69%	+$114K	﹤0.01%	2808
2023 Q4	$153K	Buy	+26,245	New	+$120K	﹤0.01%	3078

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Cubist Systematic Strategies's TCRX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its TScan Therapeutics (TCRX) stake by 76% in Q3 2025, selling an estimated $231K and leaving 42,078 shares worth $76.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

Cubist Systematic Strategies first reported a position in TCRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $352K in Q1 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

Cubist Systematic Strategies held 42,078 shares of TScan Therapeutics worth $76.6K as of Q3 2025.
Cubist Systematic Strategies sold 130,434 TScan Therapeutics shares in Q3 2025, an estimated $231K.
TScan Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2808 holding.
Cubist Systematic Strategies first reported a position in TScan Therapeutics in Q4 2023 and has held it in 7 quarters since.
Cubist Systematic Strategies's TScan Therapeutics position peaked at $352K in Q1 2024.
73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.